MOVIVA®
Turn down the food noise
MOVIVA® is the innovative, minimally invasive endoscopic solution for gastric mucosal ablation (GMA) in the fundus. It reduces the patient's hunger feeling and, when combined with Endoscopic Sleeve Gastroplasty (ESG), GMA can yield weight loss results comparable to traditional bariatric surgery.
Prof. Ivo Boskoski, Rome, Italy
“Minimally invasive endoscopic techniques that target appetite regulation through precise ablation of the gastric fundus offer patients an effective pathway to weight loss without the risks associated with surgery. MOVIVA®’s innovative injection and ablation capabilities simplify the GMA procedure and could set a new standard in endoscopic bariatric care.”
Christopher McGowan, MD, Charlotte, U.S.
“Combining GMA with ESG represents one of the most promising breakthroughs in non-surgical weight loss treatment. In our early clinical trials, this dual approach achieved total body weight loss of 23 to 24 percent - comparable to surgical sleeve gastrectomy, but without the need for surgery. Patients consistently report greater control over hunger, reduced cravings, and an improved relationship with food. These results are not just clinically significant - they are potentially life-changing.”
GMA – How it works
The GMA procedure involves ablating the mucosa of the gastric fundus. This reduces the production of ghrelin - the so-called hunger hormone, resulting in less hunger and fewer cravings. At the same time, the ablation of tissue leads to a shrinking of the fundus, reducing stomach capacity.
GMA procedure with MOVIVA®
Endoscopic ablation of the gastric fundus with MOVIVA®: First the distal fundal border is marked with dots using short activations of APC.
The area to be ablated is elevated with saline solution by means of high-pressure needle-free injection and then ablated with argon plasma coagulation (APC). These two steps are repeated until the entire area has been ablated.
When GMA is combined with ESG, the approach achieves weight loss outcomes comparable to vertical sleeve gastrectomy (VSG), while being less invasive.
A new addition to your treatment portfolio
MOVIVA® provides a viable alternative for patients who fear the side effects and risks of bariatric surgical interventions.
Start your clinical journey with MOVIVA® today
To support reliable results during GMA with MOVIVA®, we offer dedicated training courses.
These are available in various countries and regions.
Webinar: Advancing bariatric endoscopy
Three distinguished speakers - Christopher McGowan, MD, Prof. Ivo Boskoski, MD and, Abdullah AlMousa, MD - share their
insights and discuss key questions.
- Exploring Gastric Mucosal Ablation: First Clinical Insights into a New Endoscopic Therapy for Obesity - I. Boskoski, MD, Rome, Italy
- GMA in Practice: First-in-Human Insights, Tips & Tricks, and Key Safety Steps - C. McGowan MD, Charlotte, United States
- Pioneering Endoscopic GMA Fundus Treatment: Lessons from Early Clinical Experience - A. AlMousa, MD, Onaizah, Saudi Arabia
MOVIVA® – Hybrid technology for GMA
MOVIVA® is an advanced hybrid instrument designed for GMA. It combines two key
functions in one product:
- Injection of fluid to form a submucosal cushion that protects deeper tissue layers from thermal injury
- Superficial thermal ablation of the mucosa using APC.
MOVIVA® is equipped with the dedicated moveAPD® mode, delivering broad and consistent APC.
Questions?
Do you have questions about MOVIVA® or GMA?
Reach out to us - we are happy to support you!